1. Home
  2. ENTX vs FNWB Comparison

ENTX vs FNWB Comparison

Compare ENTX & FNWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • FNWB
  • Stock Information
  • Founded
  • ENTX 2010
  • FNWB 1923
  • Country
  • ENTX Israel
  • FNWB United States
  • Employees
  • ENTX N/A
  • FNWB N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • FNWB Banks
  • Sector
  • ENTX Health Care
  • FNWB Finance
  • Exchange
  • ENTX Nasdaq
  • FNWB Nasdaq
  • Market Cap
  • ENTX 90.2M
  • FNWB 95.2M
  • IPO Year
  • ENTX 2018
  • FNWB 2015
  • Fundamental
  • Price
  • ENTX $2.43
  • FNWB $11.88
  • Analyst Decision
  • ENTX Strong Buy
  • FNWB Hold
  • Analyst Count
  • ENTX 1
  • FNWB 1
  • Target Price
  • ENTX $10.00
  • FNWB $12.00
  • AVG Volume (30 Days)
  • ENTX 83.2K
  • FNWB 24.2K
  • Earning Date
  • ENTX 03-07-2025
  • FNWB 01-29-2025
  • Dividend Yield
  • ENTX N/A
  • FNWB 2.36%
  • EPS Growth
  • ENTX N/A
  • FNWB N/A
  • EPS
  • ENTX N/A
  • FNWB N/A
  • Revenue
  • ENTX $99,000.00
  • FNWB $50,900,000.00
  • Revenue This Year
  • ENTX N/A
  • FNWB N/A
  • Revenue Next Year
  • ENTX N/A
  • FNWB $11.60
  • P/E Ratio
  • ENTX N/A
  • FNWB N/A
  • Revenue Growth
  • ENTX 607.14
  • FNWB N/A
  • 52 Week Low
  • ENTX $0.95
  • FNWB $8.91
  • 52 Week High
  • ENTX $3.35
  • FNWB $16.00
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 54.06
  • FNWB 76.08
  • Support Level
  • ENTX $2.21
  • FNWB $10.80
  • Resistance Level
  • ENTX $2.62
  • FNWB $11.10
  • Average True Range (ATR)
  • ENTX 0.21
  • FNWB 0.26
  • MACD
  • ENTX -0.01
  • FNWB 0.10
  • Stochastic Oscillator
  • ENTX 69.35
  • FNWB 90.14

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About FNWB First Northwest Bancorp

First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.

Share on Social Networks: